Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  Shanghai Junshi Biosciences Co., Ltd.    1877   CNE100003FF7

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

(1877)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shanghai Junshi Biosciences : May Benefit From Covid-19 Neutralising Antibody

10/18/2020 | 10:47pm EST

Shanghai Junshi Biosciences may benefit from its Covid-19 neutralising antibody in the near term, Daiwa Capital Markets says, initiating coverage of the stock with an outperform rating and a target price of HK$60.00. The biotech company out-licensed the excluding-China rights of the antibody to Eli Lilly, and the latest trial data show promising results in treating Covid-19 together with another neutralising antibody, Daiwa notes. A new drug application for the antibody is expected to filed with the U.S. FDA in 2Q 2021, with a likely launch in 3Q. Daiwa estimates the antibody could contribute as much as CNY6.6 billion in revenue. Shanghai Junshi Biosciences shares are up 0.5% at HK$50.90. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

10-18-20 2246ET

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 1.53% 205.265 Delayed Quote.19.85%
SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 1.30% 78 End-of-day quote.37.32%
All news about SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
2020Drugmakers agree to halve prices to get on China state insurance list
RE
2020SHANGHAI JUNSHI BIOSCIENCES : Junshi Biosciences Shares Jump 3% on Supplemental ..
MT
2020Junshi Biosciences Files Clinical Trial Application for Solid Tumor Drug
MT
2020Junshi Biosciences' Tumor Drug Trial Progresses After Dosing First Patient
MT
2020SHANGHAI JUNSHI BIOSCIENCES : delays drug trials, focuses on COVID-19 treatment
RE
2020Junshi Biosciences Shares Slump 5% as Media Report Raises Safety Concerns ove..
MT
2020Shanghai Junshi Biosciences' Q3 Net Loss Widens
MT
2020SHANGHAI JUNSHI BIOSCIENCES : May Benefit From Covid-19 Neutralising Antibody
DJ
2020Fosun unit to begin U.S. trial of COVID-19 antibody treatment soon
RE
2020SHANGHAI JUNSHI BIOSCIENCES : Voluntary announcement - toripalimab for treatment..
PU
More news
Financials
Sales 2020 1 495 M 231 M 231 M
Net income 2020 -655 M -101 M -101 M
Net cash 2020 3 636 M 561 M 561 M
P/E ratio 2020 -88,7x
Yield 2020 -
Capitalization 86 549 M 11 165 M 13 352 M
EV / Sales 2020 55,5x
EV / Sales 2021 31,4x
Nbr of Employees 1 372
Free-Float 16,7%
Chart SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Duration : Period :
Shanghai Junshi Biosciences Co., Ltd. Technical Analysis Chart | 1877 | CNE100003FF7 | MarketScreener
Technical analysis trends SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 57,56 CNY
Last Close Price 78,00 CNY
Spread / Highest target -3,82%
Spread / Average Target -26,2%
Spread / Lowest Target -41,2%
EPS Revisions
Managers and Directors
NameTitle
Ning Li General Manager & Executive Director
Jun Xiong Chairman
Yu Wu Chairman-Supervisory Board
Hui Feng Executive Director
Hai Wu Non-Executive Director
Sector and Competitors